Atenolol 5mg/ml Oral Solution
- Revised
- 12/05/2026
- Source updated
- 18 May 2026
- MA number
- PL 39307/0050
- ATC
- C07AB03
- Legal status
- Prescription only medicine
Indications
Concepts (33)
+Heart conditionsContraindicated
Atenolol, as with other beta-blockers, should not be used in patients with any of the following: • known hypersensitivity to the active substance, or any of the excipients listed in section 6.1• cardiogenic shock• uncontrolled heart failure• sick sinus syndrome• second-or third-degree heart block• untreated phaeochromocytoma• metabolic acidosis• bradycardia (<45 bpm)• hypotension• severe peripheral arterial c
Source SmPC ↗+Hormone disordersContraindicated
known hypersensitivity to the active substance, or any of the excipients listed in section 6.1• cardiogenic shock• uncontrolled heart failure• sick sinus syndrome• second-or third-degree heart block• untreated phaeochromocytoma• metabolic acidosis• bradycardia (<45 bpm)• hypotension• severe peripheral arterial circulatory disturbances
Source SmPC ↗+Heart rhythm blockContraindicated
d not be used in patients with any of the following: • known hypersensitivity to the active substance, or any of the excipients listed in section 6.1• cardiogenic shock• uncontrolled heart failure• sick sinus syndrome• second-or third-degree heart block• untreated phaeochromocytoma• metabolic acidosis• bradycardia (<45 bpm)• hypotension• severe peripheral arterial circulatory disturbances
Source SmPC ↗+Allergy to the medicineContraindicated
Atenolol, as with other beta-blockers, should not be used in patients with any of the following: • known hypersensitivity to the active substance, or any of the excipients listed in section 6.1• cardiogenic shock• uncontrolled heart failure• sick sinus syndrome• second-or third-degree heart block• untreated phaeochromocytoma• metabolic acidosis• bradycardia (<45 bpm)• hypotension• severe pe
Source SmPC ↗+Low blood pressureContraindicated
listed in section 6.1• cardiogenic shock• uncontrolled heart failure• sick sinus syndrome• second-or third-degree heart block• untreated phaeochromocytoma• metabolic acidosis• bradycardia (<45 bpm)• hypotension• severe peripheral arterial circulatory disturbances
Source SmPC ↗+Acid build-up in the bloodContraindicated
active substance, or any of the excipients listed in section 6.1• cardiogenic shock• uncontrolled heart failure• sick sinus syndrome• second-or third-degree heart block• untreated phaeochromocytoma• metabolic acidosis• bradycardia (<45 bpm)• hypotension• severe peripheral arterial circulatory disturbances
Source SmPC ↗+ShockContraindicated
Atenolol, as with other beta-blockers, should not be used in patients with any of the following: • known hypersensitivity to the active substance, or any of the excipients listed in section 6.1• cardiogenic shock• uncontrolled heart failure• sick sinus syndrome• second-or third-degree heart block• untreated phaeochromocytoma• metabolic acidosis• bradycardia (<45 bpm)• hypotension• severe peripheral arterial c
Source SmPC ↗+UnclassifiedContraindicated
Atenolol, as with other beta-blockers, should not be used in patients with any of the following: • known hypersensitivity to the active substance, or any of the excipients listed in section 6.1• cardiogenic shock• uncontrolled heart failure• sick sinus syndrome• second-or third-degree heart bl
Source SmPC ↗+Blood vessel conditionsContraindicated
ction 6.1• cardiogenic shock• uncontrolled heart failure• sick sinus syndrome• second-or third-degree heart block• untreated phaeochromocytoma• metabolic acidosis• bradycardia (<45 bpm)• hypotension• severe peripheral arterial circulatory disturbances
Source SmPC ↗+Angioedema (deep swelling)Warning
en given to patients with a history of anaphylactic reaction to such allergens. Such patients may be unresponsive to the usual doses of adrenaline (epinephrine) used to treat the allergic reactions.• May cause a hypersensitivity reaction including angioedema and urticaria.• Should be used with caution in the elderly, starting with a lesser dose (see Section 4.2). Since Atenolol is excreted via the kidneys, dosage should be reduced in patients with a creatinine clearan
Source SmPC ↗+Benzyl alcoholWarning
ve discussed these symptoms with the prescribing doctor”. As with other beta-blockers, in patients with a phaeochromocytoma, an alpha-blocker should be given concomitantly. Excipient warning: Methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216): May cause allergic reactions (possibly delayed). Sorbitol (E420): This medicinal product contains 280mg sorbitol in each ml. Patients with hereditary fructose intolerance (HFI) should not take/be given this medicinal product. Sodium: This medic
Source SmPC ↗+Obstructed blood flow from the heartWarning
the elderly, starting with a lesser dose (see Section 4.2). Since Atenolol is excreted via the kidneys, dosage should be reduced in patients with a creatinine clearance of below 35 ml/min/1.73 m2. Although cardioselective (beta1) beta-blockers may have less effect on lung function than non-selective beta-blockers, as with all beta-blockers, these should be avoided in patients with reversible obstructive airways disease, unless there are compelling clinical reasons for their use. Where such reasons exist, Atenolol may be used with caution. Occasionally, some increase in airways resistance may occur in asthmatic patients however, and this may usually be reversed by commonly used dosage of bronchodilators such as salbutamol or isoprenaline. The label and patient information leaflet for this product state the following warning: “If you have ever had asthma or wheezing, you should not take this medicine unless you have discussed these symptoms with the prescribing doctor”. As with other beta-blockers, in patients with a phaeochromocytoma, an alpha-blocker should be given concomitantly. Excipient warning: Methyl parahydroxybenzoate (E218) and propyl parahydroxyb
Source SmPC ↗+Taken with other medicinesWarning
aflet for this product state the following warning: “If you have ever had asthma or wheezing, you should not take this medicine unless you have discussed these symptoms with the prescribing doctor”. As with other beta-blockers, in patients with a phaeochromocytoma, an alpha-blocker should be given concomitantly. Excipient warning: Methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216): May cause allergic reactions (possibly delayed). Sorbitol (E420): This medicinal product contains
Source SmPC ↗+Older peopleWarning
ens. Such patients may be unresponsive to the usual doses of adrenaline (epinephrine) used to treat the allergic reactions.• May cause a hypersensitivity reaction including angioedema and urticaria.• Should be used with caution in the elderly, starting with a lesser dose (see Section 4.2). Since Atenolol is excreted via the kidneys, dosage should be reduced in patients with a creatinine clearance of below 35 ml/min/1.73 m2. Although cardioselective (beta1) beta-blockers may have less
Source SmPC ↗+Intolerance to an ingredientWarning
, an alpha-blocker should be given concomitantly. Excipient warning: Methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216): May cause allergic reactions (possibly delayed). Sorbitol (E420): This medicinal product contains 280mg sorbitol in each ml. Patients with hereditary fructose intolerance (HFI) should not take/be given this medicinal product. Sodium: This medicinal product contains 2.79mg sodium per ml, equivalent to 0.14% of the WHO recommended maximum daily intake of 2 g sodium for an adult. Propylene glycol (E1520): This medicinal
Source SmPC ↗+Sugar alcoholsWarning
, an alpha-blocker should be given concomitantly. Excipient warning: Methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216): May cause allergic reactions (possibly delayed). Sorbitol (E420): This medicinal product contains 280mg sorbitol in each ml. Patients with hereditary fructose intolerance (HFI) should not take/be given this medicinal product. Sodium: This medicinal product contains 2.79mg sodium per ml, equivalent to 0.14% of the WHO recommended maximum daily intake of 2 g sodium for an adult. Propylene glycol (E1520): This medicinal
Source SmPC ↗+Propylene glycolWarning
not take/be given this medicinal product. Sodium: This medicinal product contains 2.79mg sodium per ml, equivalent to 0.14% of the WHO recommended maximum daily intake of 2 g sodium for an adult. Propylene glycol (E1520): This medicinal product contains 3.03mg propylene glycol in each ml.
Source SmPC ↗+Kidney conditionsWarning
on. In the rare instances when a treated patient develops symptoms which may be attributable to a slow heart rate and the pulse rate drops to less than 50–55 bpm at rest, the dose should be reduced.• May cause a more severe reaction to a variety of allergens when given to patients with a history of anaphylactic reaction to such allergens. Such patients may be unresponsive to the usual doses of adrenaline (epinephrine) used to treat the allergic reactions.• May cause a hypersensitivity reaction including angioedema and urticaria.• Should be used with caution in the elderly, starting with a lesser dose (see Section 4.2). Since Atenolol is excreted via
Source SmPC ↗+Breathing conditionsWarning
the elderly, starting with a lesser dose (see Section 4.2). Since Atenolol is excreted via the kidneys, dosage should be reduced in patients with a creatinine clearance of below 35 ml/min/1.73 m2. Although cardioselective (beta1) beta-blockers may have less effect on lung function than non-selective beta-blockers, as with all beta-blockers, these should be avoided in patients with reversible obstructive airways disease, unless there are compelling clinical reasons for their use. Where such reasons exist, Atenolol may be used with caution. Occasionally, some increase in airways resistance may occur in asthmatic patients however, and this may usually be reversed by commonly used dosage of bronchodilators such as salbutamol or isoprenaline. The label and patient information leaflet for this product state the following warning: “If you have ever had asthma or wheezing, you should not take this medicine unless you have discussed these symptoms with the prescribing doctor”. As with other beta-blockers, in patients with a phaeochromocytoma, an alpha-blocker should be given concomitantly. Excipient warning: Methyl parahydroxybenzoate (E218) and propyl parahydroxyb
Source SmPC ↗+ThyroidWarning
s could further increase the risk of severe hypoglycaemia when used concurrently with sulfonylureas. Diabetic patients should be advised to carefully monitor blood glucose levels. (see Section 4.5).• May mask the signs of thyrotoxicosis• Will reduce heart rate as a result of its pharmacological action. In the rare instances when a treated patient develops symptoms which may be attributable to a slow heart rate and the pulse rate dro
Source SmPC ↗+Heart rhythm (QT interval)Interaction
clonidine by beta-blocker therapy, the introduction of beta-blockers should be delayed for several days after clonidine administration has stopped. (See also prescribing information for clonidine). Class I anti-arrhythmic drugs (e.g. disopyramide) and amiodarone may have a potentiating effect on atrial-conduction time and induce negative inotropic effect. Concomitant use of sympathomimetic agents, e.g. adrenaline (epinephrine), may counteract the effect of beta-blockers. Concomitant use with insulin and oral antidiabetic drugs may lead to the intens
Source SmPC ↗+BreastfeedingPregnancy
Caution should be exercised when Atenolol is administered during pregnancy or to a woman who is breast-feeding. Pregnancy Atenolol crosses the placental barrier and appears in the cord blood. No studies have been performed on the use of Atenolol in the first trimester and the possibility of foetal injury c
Source SmPC ↗+FertilityPregnancy
There is significant accumulation of Atenolol in breast milk. Neonates born to mothers who are receiving Atenolol at parturition or breast-feeding may be at risk of hypoglycaemia and bradycardia. Fertility No human data on the effect of atenolol on fertility are available. In rats, there was no effect on mating or fertility with atenolol treatment.
Source SmPC ↗+Liver conditionsPregnancy
ent of hypertension in the third trimester. Administration of Atenolol to pregnant women in the management of mild to moderate hypertension has been associated with intra-uterine growth retardation. The use of Atenolol in women who are, or may become, pregnant requires that the anticipated benefit be weighed against the possible risks, particularly in the first and second trimesters, since beta-blockers, in general, have been associated with a decrease in placental perfusion which may result in intra-uterine deaths, immature and premature deliveries. Breast-feeding There is significant accumulation of Atenolol in breast milk. Neonates born to mothers who are receiving Atenolol at parturition or breast-feeding may be at risk of hypoglycaemia
Source SmPC ↗+ChildrenPregnancy
d with a decrease in placental perfusion which may result in intra-uterine deaths, immature and premature deliveries. Breast-feeding There is significant accumulation of Atenolol in breast milk. Neonates born to mothers who are receiving Atenolol at parturition or breast-feeding may be at risk of hypoglycaemia and bradycardia. Fertility No human data on the effect of atenolol on fertility are available. In rats, there was no effect on mating or fertility with atenolol treatment.
Source SmPC ↗+PregnancyPregnancy
Caution should be exercised when Atenolol is administered during pregnancy or to a woman who is breast-feeding. Pregnancy Atenolol crosses the placental barrier and appears in the cord blood. No studies have been performed on the use of Atenolol in the first trimester and the possibility of foetal injury c
Source SmPC ↗+AlcoholNot in scanned sections
+Contrast dyes used in scansNot in scanned sections
+Salt and mineral balanceNot in scanned sections
+Stomach and gutNot in scanned sections
+Sodium and potassium contentNot in scanned sections
+BlockageNot in scanned sections
+Eye conditionsNot in scanned sections
Storage and shelf life
§6.3 — Shelf life
18 months
For 100ml and 150ml: Discard 30 days after first opening.
For 300ml: Discard 60 days after first opening.
§6.4 — Special precautions for storage
Do not store above 25°C.